Armin Giese

Active 1995–2025

103
Papers
19,554
Citations
75
h-index
100
i10-index

Citations

Citations per year for Armin Giese1922: 3 citations1980: 1 citations1996: 2 citations1997: 4 citations1998: 22 citations1999: 38 citations2000: 50 citations2001: 79 citations2002: 74 citations2003: 66 citations2004: 91 citations2005: 88 citations2006: 95 citations2007: 72 citations2008: 83 citations2009: 112 citations2010: 142 citations2011: 145 citations2012: 159 citations2013: 111 citations2014: 114 citations2015: 146 citations2016: 188 citations2017: 220 citations2018: 190 citations2019: 723 citations2020: 765 citations2021: 769 citations2022: 641 citations2023: 509 citations2024: 806 citations2025: 393 citations2026: 5 citations1923–1979: no citations, so these years are not shown1981–1995: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,925 citing papers, 20.9% of this breakdownGermany: 916 citing papers, 9.9% of this breakdownUnited Kingdom: 847 citing papers, 9.2% of this breakdownItaly: 631 citing papers, 6.9% of this breakdownChina: 523 citing papers, 5.7% of this breakdownFrance: 362 citing papers, 3.9% of this breakdownCanada: 344 citing papers, 3.7% of this breakdownSpain: 321 citing papers, 3.5% of this breakdownSweden: 265 citing papers, 2.9% of this breakdownJapan: 262 citing papers, 2.8% of this breakdownAustralia: 240 citing papers, 2.6% of this breakdownNetherlands: 230 citing papers, 2.5% of this breakdown
0%20.9%Other 25.5%

Fields

  • Medicine53.1%
  • Biochemistry, Genetics and Molecular Biology33.8%
  • Neuroscience7%
  • Engineering1.2%
  • Nursing1.1%
  • Mathematics0.9%
  • Other2.9%

Topics

  • Parkinson's Disease Mechanisms and Treatments11%
  • Alzheimer's disease research and treatments8.3%
  • Prion Diseases and Protein Misfolding6.1%
  • Neurological diseases and metabolism4.4%
  • Neurological disorders and treatments4.3%
  • Trace Elements in Health2.5%
  • Other63.4%

Coauthors

All papers

Open in search
  1. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jan Kassubek, Florian Krismer, Johannes Levin, Stefan Lorenzl, Huw R. Morris, Peter J. Nestor, Wolfgang H. Oertel, Werner Poewe, Gil D. Rabinovici, James B. Rowe, Gerard D. Schellenberg, Klaus Seppi, Thilo van Eimeren, Gregor K. Wenning, Adam L. Boxer, Lawrence I. Golbe, Irene Litvan, for the Movement Disorder Society–endorsed PSP Study Group - Movement Disorders 2017 cited by 2,332

  2. Distribution patterns of tau pathology in progressive supranuclear palsy

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Acta Neuropathologica 2020 cited by 471

  3. Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christian Griesinger, Armin Giese - Acta Neuropathologica 2013 cited by 456

  4. Tau deposition patterns are associated with functional connectivity in primary tauopathies

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jost J. Rumpf, Matthias L. Schroeter, Joseph Claßen, Victor L. Villemagne, John Seibyl, Andrew Stephens, Edward B. Lee, David G. Coughlin, Armin Giese, Murray Grossman, Corey T. McMillan, Ellen Gelpí, Laura Molina‐Porcel, Yaroslau Compta, John C. van Swieten, Laura Donker Laat, Claire Troakes, Safa Al‐Sarraj, John Robinson, Sharon X. Xie, David J. Irwin, Sigrun Roeber, Jochen Herms, Mikael Simons, Peter Bartenstein, Virginia M. Lee, John Q. Trojanowski, Johannes Levin, Günter U. Höglinger, Michael Ewers - Nature Communications 2022 cited by 108

  5. Different Species of α-Synuclein Oligomers Induce Calcium Influx and Seeding

    Authors: , , , , , , , , - Journal of Neuroscience 2007 cited by 798

  6. Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , John C. van Swieten, Alex Rajput, Leslie W. Ferguson, Mark Cookson, J. Raphael Gibbs, Cornelis Blauwendraat, Jinhui Ding, Ruth Chia, Bryan J. Traynor, Alexander Pantelyat, Coralie Viollet, Bryan J. Traynor, Olga Pletniková, Juan C. Troncoso, Liana S. Rosenthal, Adam L. Boxer, Gesine Respondek, Thomas Arzberger, Sigrun Roeber, Armin Giese, David J. Burn, Nicola Pavese, Alexander Gerhard, Christopher Kobylecki, P. Nigel Leigh, Alistair Church, Michele T.M. Hu - The Lancet Neurology 2020 cited by 120

  7. Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial

    Authors: , , , , , , , , , , , , , , , , - EBioMedicine 2022 cited by 85

  8. The phenotypic spectrum of progressive supranuclear palsy: A retrospective multicenter study of 100 definite cases

    Authors: , , , , , , , , , , , , , , , , , , - Movement Disorders 2014 cited by 379

  9. Cost of Migration: Invasion of Malignant Gliomas and Implications for Treatment

    Authors: , , , - Journal of Clinical Oncology 2003 cited by 1,206

  10. The Differential Diagnosis and Treatment of Atypical Parkinsonism

    Authors: , , , , - Deutsches Ärzteblatt international 2016 cited by 212

  11. Cardiolipin Promotes Pore-Forming Activity of Alpha-Synuclein Oligomers in Mitochondrial Membranes

    Authors: , , , , , , , , , , , - ACS Chemical Neuroscience 2019 cited by 109

  12. DNA methylation analysis on purified neurons and glia dissects age and Alzheimer’s disease-specific changes in the human cortex

    Authors: , , , , , , , , , , , , , , , , - Epigenetics & Chromatin 2018 cited by 256

  13. How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Huw R. Morris, Jennifer L. Whitwell, Yaroslau Compta, Jean‐Christophe Corvol, Anthony E. Lang, James B. Rowe, Günter U. Höglinger, for the Movement Disorder Society‐endorsed PSP Study Group - Movement Disorders 2019 cited by 142

  14. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson’s disease model

    Authors: , , , , , , , , , , , , - Acta Neuropathologica 2019 cited by 126

  15. MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity

    Authors: , , , , , , , , , , - Neuro-Oncology 2012 cited by 302

  16. [11C]MODAG-001—towards a PET tracer targeting α-synuclein aggregates

    Authors: , , , , , , , , , , , , , , - European Journal of Nuclear Medicine and Molecular Imaging 2020 cited by 93

  17. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects

    Authors: , , , , , , , , , , , , , , , , , - Annals of Neurology 1999 cited by 1,449

  18. Quantifying prion disease penetrance using large population control cohorts

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jesús de Pedro‐Cuesta, Stéphane Haı̈k, Jean Laplanche, Élodie Bouaziz-Amar, J.-P. Brandel, Sabina Capellari, Piero Parchi, Anna Poleggi, Anna Ladogana, Anne O’Donnell‐Luria, Konrad J. Karczewski, Jamie L. Marshall, Michael Boehnke, Markku Laakso, Karen L. Mohlke, Anna K. Kähler, Kimberly Chambert, Steven A. McCarroll, Patrick F. Sullivan, Christina M. Hultman, Shaun Purcell, Pamela Sklar, Sven J. van der Lee, Annemieke J.M. Rozemüller, Casper Jansen, Albert Hofman, Robert Kraaij, Jeroen van Rooij, M. Arfan Ikram, André G. Uitterlinden, Cornelia M. van Duijn, Mark J. Daly, Daniel G. MacArthur - Science Translational Medicine 2016 cited by 469

  19. Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Neurology Neurosurgery & Psychiatry 2017 cited by 129

  20. Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Marco Düring, Jens Ebentheuer, Christopher Fricke, Alexander L. Gerbes, Stefan Jun Groiss, Doreen Gruber, Christian J. Hartmann, Thomas Kirchner, Daniel Kroneberg, Martin Kunz, Stefan Lorenzl, Alexia Moldovan, Anna H. Noda, Heidi Pape, Gesine Respondek, Eva Schäffer, Martina Schneider, Alfons Schnitzler, Walter Schulz‐Schaeffer, Johannes Schwarz, Cornelia Skowronek, Alexander Storch, Vera Tadić, Dávid Vadász, Benno F. Zimmermann - The Lancet Neurology 2019 cited by 126

  21. Copathology in Progressive Supranuclear Palsy: Does It Matter?

    Authors: , , , , , , , , , , , , - Movement Disorders 2020 cited by 88

  22. Inhibition of mitochondrial fusion by α‐synuclein is rescued by PINK1, Parkin and DJ‐1

    Authors: , , , , , , , , , , , , - The EMBO Journal 2010 cited by 477

  23. Which ante mortem clinical features predict progressive supranuclear palsy pathology?

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Stefan Lorenzl, Huw R. Morris, Peter J. Nestor, Wolfgang H. Oertel, Gil D. Rabinovici, James B. Rowe, Thilo van Eimeren, Gregor K. Wenning, Adam L. Boxer, Lawrence I. Golbe, Irene Litvan, María Stamelou, Günter U. Höglinger, for the Movement Disorder Society‐Endorsed PSP Study Group - Movement Disorders 2017 cited by 164

  24. Anle138b modulates α‐synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy

    Authors: , , , , , , , - Movement Disorders 2018 cited by 115